NADH, NADPH Oxidoreductases
"NADH, NADPH Oxidoreductases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6.
| Descriptor ID |
D009247
|
| MeSH Number(s) |
D08.811.682.608
|
| Concept/Terms |
NADH, NADPH Oxidoreductases- NADH, NADPH Oxidoreductases
- NADPH Oxidoreductases NADH
- Oxidoreductases NADH, NADPH
- Oxidoreductases, NADH, NADPH
|
Below are MeSH descriptors whose meaning is more general than "NADH, NADPH Oxidoreductases".
Below are MeSH descriptors whose meaning is more specific than "NADH, NADPH Oxidoreductases".
This graph shows the total number of publications written about "NADH, NADPH Oxidoreductases" by people in this website by year, and whether "NADH, NADPH Oxidoreductases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NADH, NADPH Oxidoreductases" by people in Profiles.
-
Pang Y, Cheng X, Huhman DV, Ma J, Peel GJ, Yonekura-Sakakibara K, Saito K, Shen G, Sumner LW, Tang Y, Wen J, Yun J, Dixon RA. Medicago glucosyltransferase UGT72L1: potential roles in proanthocyanidin biosynthesis. Planta. 2013 Jul; 238(1):139-54.
-
Pant S, Burris HA, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93.
-
Bamford VA, Armour M, Mitchell SA, Cartron M, Andrews SC, Watson KA. Preliminary X-ray diffraction analysis of YqjH from Escherichia coli: a putative cytoplasmic ferri-siderophore reductase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Sep 01; 64(Pt 9):792-6.
-
Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang S, Garrett MW, Chandrasekaran S, Matsuzaki S, Szweda LI, Gordon BE, Kem DC. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol. 2007 Feb 19; 6:6.
-
Ungvari Z, Csiszar A, Huang A, Kaminski PM, Wolin MS, Koller A. High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase. Circulation. 2003 Sep 09; 108(10):1253-8.
-
Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, Kaley G. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res. 2002 Jun 14; 90(11):1159-66.
-
Chen CL, Sangiah S, Yu CA, Chen H, Berlin KD, Garrison GL, Scherlag BJ, Lazzara R. Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPase. Res Commun Mol Pathol Pharmacol. 1994 Aug; 85(2):193-208.